Smoking and prostate cancer–Specific mortality after diagnosis in a large prospective cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 6, 2018, Pages 665-672

  Gansler, Ted ^a   Shah, Roma ^a,c   Wang, Ying ^a   Stevens, Victoria L ^a   Yang, Baiyu ^b   Newton, Christina C ^a   Gapstur, Susan M ^a   Jacobs, Eric J ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CIGARETTE SMOKING; COHORT ANALYSIS; GLEASON SCORE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK FACTOR; SMOKING CESSATION; VERY ELDERLY; CANCER SURVIVOR; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SMOKING;

AGED; AGED, 80 AND OVER; CANCER SURVIVORS; COHORT STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SMOKING;

EID: 85047918684     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-17-0890     Document Type: Article

References (32)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
2. Giovannucci E, Rimm EB, Ascherio A, Colditz GA, Spiegelman D, Stampfer MJ, et al. Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev 1999;8:277–82.
3. Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 2012;14: 365–74.
4. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014;66:1054–64.
5. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Available from: https://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html.
6. Prueitt RL, Wallace TA, Glynn SA, Yi M, Tang W, Luo J, et al. An immune-inflammation gene expression signature in prostate tumors of smokers. Cancer Res 2016;76:1055–65.
7. Shui IM, Wong CJ, Zhao S, Kolb S, Ebot EM, Geybels MS, et al. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer 2016;122:2168–77.
8. Birrane G, Li H, Yang S, Tachado SD, Seng S. Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion. Int J Oncol 2013;42:1919–28.
9. Yang S, Long M, Tachado SD, Seng S. Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix. Mol Med Rep 2015;12: 6990–96.
10. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control 2008;19:25–31.
11. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA 2011;305: 2548–55.
12. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Co-operberg MR, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer 2014;120: 197–204.
13. Murta-Nascimento C, Romero AI, Sala M, Lorente JA, Bellmunt J, Rodero NJ, et al. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona. Eur J Cancer Prev 2014.
14. Pantarotto J, Malone S, Dahrouge S, Gallant V, Eapen L. Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy. BJU Int 2007;99:564–9.
15. Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S, et al. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol 2004;171:1543–6.
16. Polesel J, Gini A, Dal Maso L, Stocco C, Birri S, Taborelli M, et al. The negative impact of tobacco smoking on survival after prostate cancer diagnosis. Cancer Causes Control 2015;26:1299–305.
17. Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU Int 2015;116:596–603.
18. Taira AV, Merrick GS, Galbreath RW, Butler WM, Bennett A, Adamovich E, et al. Prognostic importance of tobacco use in men receiving definitive prostate brachytherapy. Brachytherapy 2012;11:446–51.
19. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol 2014;32:3716–22.
20. Wang Y, Jacobs EJ, Newton CC, McCullough ML. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II nutrition cohort. Int J Cancer 2016;138:2846–55.
21. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American cancer society Cancer Prevention Study II nutrition cohort: rationale, study design, and baseline characteristics. Cancer 2002;94: 2490–501.
22. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993;137:235–41.
23. Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 2000;163:519–23.
24. Hoffman RM, Stone SN, Hunt WC, Key CR, Gilliland FD. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. Ann Epidemiol 2003;13:450–4.
25. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001;93:1822–3.
26. Adamo M, Dickie L, Ruhl J. SEER Program Coding and Staging Manual 2016; 2016. Available from: https://seer.cancer.gov/manuals/2016/SPCSM_2016_maindoc.pdf.
27. Mohler JL. Prostate cancer version 3.2016. NCCN Clinical Practice Guidelines in Oncology 2016. Available from: www.nccn.org
28. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, et al. Smoking and mortality–beyond established causes. N Engl J Med 2015; 372:631–40.
29. Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst 2011;103:835–8.
30. Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, et al. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. Eur Urol 2015;68:949–56.
31. Tay KJ, Mendez M, Moul JW, Polascik TJ. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol 2015; 25:185–90.
32. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol 2013;14:97–108.